Alexion ALXN1720-MG-301 PREVAIL
STUDY AND PROTOCOL
ALXN1720-MG-301
STUDY DETAILS
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis
FURTHER INFORMATION
Clinicaltrials.gov Identifier: NCT05556096